{"entity":{"id":"nct02830724","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","aka":[],"tldr":"A phase 1/2 trial of cyclophosphamide, fludarabine and aldesleukin (high-dose IL-2) in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers is a phase 1/2, interventional study registered as NCT02830724 by National Cancer Institute (NCI), with a registry enrolment figure of 124 participants, started 2017-04-06 and due to reach its primary completion in 2029-01-01. Interventions recorded: Cyclophosphamide; Fludarabine; Aldesleukin; Anti-hCD70 CAR transduced PBL. Conditions listed: Pancreatic Cancer; Renal Cell Cancer; Breast Cancer; Melanoma; Ovarian Cancer. Primary outcome: Frequency and severity of treatment-related adverse events; Response rate. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02830724","url":"https://clinicaltrials.gov/study/NCT02830724"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["car-t","cytotoxic-chemotherapy"],"targets":[],"drugs":["cyclophosphamide","fludarabine","aldesleukin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02830724","phase":"1/2","setting":"A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers","sponsor":"National Cancer Institute (NCI)","enrolled":124,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02830724/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}